Published in J Psychiatry Neurosci on November 01, 1991
Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (Berl) (2004) 2.74
Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology (Berl) (1997) 1.16
The behavioral actions of lithium in rodent models: leads to develop novel therapeutics. Neurosci Biobehav Rev (2007) 1.12
Animal model of menopausal depressive-like state in female mice: prolongation of immobility time in the forced swimming test following ovariectomy. Psychopharmacology (Berl) (2005) 0.95
Effect of potassium channel modulators in mouse forced swimming test. Br J Pharmacol (1999) 0.88
Rate-dependent behavioral effects of stimulation of central motoric alpha(1)-adrenoceptors: hypothesized relation to depolarization blockade. Psychopharmacology (Berl) (2005) 0.79
Antidepressant-like effects of guanfacine and sex-specific differences in effects on c-fos immunoreactivity and paired-pulse ratio in male and female mice. Psychopharmacology (Berl) (2015) 0.76
The effect of sympathetic antagonists on the antidepressant action of alprazolam. Libyan J Med (2008) 0.75
Clonidine potentiates the effects of tranylcypromine, phenelzine and two analogues in the forced swimming test in mice. J Psychiatry Neurosci (2002) 0.75
Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther (1977) 8.46
Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology (Berl) (1988) 2.19
The validity of animal models of depression. Psychopharmacology (Berl) (1984) 2.07
Clinical pharmacokinetics of bupropion: a review. J Clin Psychiatry (1983) 1.03
Antidepressant-like action of 5-HT1A agonists and conventional antidepressants in an animal model of depression. Eur J Pharmacol (1987) 0.96
Dihydropyridine calcium channel antagonists reduce immobility in the mouse behavioral despair test; antidepressants facilitate nifedipine action. Eur J Pharmacol (1987) 0.92
A beta adrenergic stimulant (salbutamol) versus clomipramine in depression: a controlled study. Br J Psychiatry (1980) 0.92
Reversal of behavioral depression by infusion of an alpha-2 adrenergic agonist into the locus coeruleus. Neuropharmacology (1986) 0.90
Infusion of adrenergic receptor agonists and antagonists into the locus coeruleus and ventricular system of the brain. Effects on swim-motivated and spontaneous motor activity. Neuropharmacology (1986) 0.89
Involvement of alpha- and beta 1-adrenergic mechanisms in the immobility-reducing action of desipramine in the forced swimming test. Neuropharmacology (1983) 0.86
Minaprine, a new drug with antidepressant properties. Drugs Exp Clin Res (1985) 0.82
Fengabine, a novel antidepressant GABAergic agent. I. Activity in models for antidepressant drugs and psychopharmacological profile. J Pharmacol Exp Ther (1987) 0.82
A 2-amino-2-oxazoline derivative as an antidepressant in mice. Arzneimittelforschung (1988) 0.81
Additive effects of clonidine and antidepressant drugs in the mouse forced-swimming test. Psychopharmacology (Berl) (1988) 0.81
[The new versus the old antidepressant drugs: a comparative study of their psychopharmacological profiles (author's transl)]. Encephale (1981) 0.79
Morphologic, biochemical, and molecular evidence of apoptosis during the reperfusion phase after brief periods of renal ischemia. Am J Pathol (1992) 1.80
International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev (1999) 1.74
Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers. Am J Psychiatry (1995) 1.59
Tardive dyskinesia: legal and preventive aspects. Can J Psychiatry (1990) 1.47
Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers. Am J Psychiatry (1993) 1.40
Intrathecal anesthesia: ropivacaine versus bupivacaine. Anesth Analg (2000) 1.21
Additive effects of lithium and antidepressants in the forced swimming test: further evidence for involvement of the serotoninergic system. Psychopharmacology (Berl) (1994) 1.12
[Enhancement of nociceptive reactions by naloxone in mice and rats (author's transl)]. Psychopharmacologia (1974) 1.06
Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology (Berl) (1998) 1.04
Intrathecal bupivacaine in humans: influence of volume and baricity of solutions. Anesthesiology (1999) 0.99
Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones. Nature (1984) 0.98
Influence of age on behavioural response in the light/dark paradigm. Physiol Behav (1999) 0.98
Neuroanatomic correlates of CCK-4-induced panic attacks in healthy humans: a comparison of two time points. Biol Psychiatry (1999) 0.94
CCK in animal and human research on anxiety. Trends Pharmacol Sci (1993) 0.94
Neuronal network of panic disorder: the role of the neuropeptide cholecystokinin. Depress Anxiety (2012) 0.91
Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans. Neuropsychopharmacology (1999) 0.91
Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry (1999) 0.89
Activation of amygdala cholecystokininB receptors potentiates the acoustic startle response in the rat. J Neurosci (1997) 0.89
Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci (1997) 0.88
Comparison of antidepressant activity in 4- and 40-week-old male mice in the forced swimming test: involvement of 5-HT1A and 5-HT1B receptors in old mice. Psychopharmacology (Berl) (2001) 0.87
Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers. Depress Anxiety (1998) 0.87
The role of the beta-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms. Biol Psychiatry (1998) 0.87
The urodynamic effects of intravenous opioids and ketoprofen in humans. Anesth Analg (1998) 0.86
Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in health volunteers. Eur Neuropsychopharmacol (1991) 0.85
Psychopharmacological profile of the selective serotonin reuptake inhibitor, paroxetine: implication of noradrenergic and serotonergic mechanisms. J Psychopharmacol (1998) 0.85
A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study. Psychopharmacology (Berl) (1992) 0.84
Neurobiology of panic disorder. J Psychosom Res (1998) 0.84
Hyperplasia and apoptosis. Opposing cellular processes that regulate the response of the rabbit bladder to transient outlet obstruction. Lab Invest (1994) 0.83
[Precipitation and prevention of abstinence in acutely morphinized rats and mice: comparisons between naloxone, naltrexone, and diprenorphine (author's transl)]. Psychopharmacology (Berl) (1976) 0.83
Evaluation of efficacies of different classes of antidepressants in the forced swimming test in mice at different ages. Prog Neuropsychopharmacol Biol Psychiatry (1998) 0.83
Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Biol Psychiatry (1996) 0.82
Pharmacodynamic dose-response and safety study of cisatracurium (51W89) in adult surgical patients during N2O-O2-opioid anesthesia. Anesth Analg (1996) 0.82
A 2-amino-2-oxazoline derivative as an antidepressant in mice. Arzneimittelforschung (1988) 0.81
Differential effects of clonidine, lithium and quinine in the forced swimming test in mice for antidepressants: possible roles of serotoninergic systems. Eur Neuropsychopharmacol (1996) 0.81
Additive effects of clonidine and antidepressant drugs in the mouse forced-swimming test. Psychopharmacology (Berl) (1988) 0.81
Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice. Pharmacol Biochem Behav (2000) 0.81
The influence of Type A behavior pattern on the response to the panicogenic agent CCK-4. J Psychosom Res (2001) 0.80
Comparison of behavioral effects after single and repeated administrations of four benzodiazepines in three mice behavioral models. J Psychiatry Neurosci (1992) 0.79
Development of a sensitive and specific assay system for cholecystokinin tetrapeptide. Peptides (1997) 0.79
High neuroleptic plasma levels in patients manifesting supersensitivity psychosis. Biol Psychiatry (1982) 0.79
Impaired exploratory behaviour after DSP-4 treatment in rats: implications for the increased anxiety after noradrenergic denervation. Eur Neuropsychopharmacol (1995) 0.79
MMPI profiles of acute and chronic PTSD in a civilian sample. J Trauma Stress (1996) 0.79
CCK4-induced panic in healthy subjects I: psychological and cardiovascular effects. Eur Neuropsychopharmacol (1999) 0.79
[Opinion of different professional categories about the intensity of procedural pain in adult intensive care units]. Ann Fr Anesth Reanim (2010) 0.79
Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry (1992) 0.79
Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats. Naunyn Schmiedebergs Arch Pharmacol (1994) 0.79
Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam. Prog Neuropsychopharmacol Biol Psychiatry (1995) 0.78
Effects of CCK-4 infusion on the acoustic eye-blink startle and psychophysiological measures in healthy volunteers. J Psychopharmacol (1999) 0.78
Effects of single oral doses of bromazepam, buspirone and clobazam on performance tasks and memory. Neuropsychobiology (1989) 0.78
Subdiaphragmatic vagotomy does not prevent the anti-exploratory effect of caerulein in the elevated plus-maze. Neuropeptides (1994) 0.78
Tardive dyskinesia in a nonpsychiatric patient due to short-term use of a neuroleptic/anticholinergic combination drug. Can Med Assoc J (1982) 0.78
A randomized trial of sertraline, self-administered cognitive behavior therapy, and their combination for panic disorder. Psychol Med (2010) 0.78
[5-HT1B serotonin receptors and antidepressant effects of selective serotonin reuptake inhibitors ]. C R Acad Sci III (2001) 0.78
Inhibition of nitric oxide synthase causes anxiolytic-like behaviour in an elevated plus-maze. Neuroreport (1995) 0.78
Effect of aging on cholecystokinin-induced panic. Am J Psychiatry (1998) 0.78
Cholecystokinin receptor agonists block the jumping behaviour precipitated in morphine-dependent mice by naloxone. Eur Neuropsychopharmacol (1999) 0.78
Sedation caused by clonidine in patients with spinal cord injury. Br J Anaesth (2003) 0.78
Neurobiology of panic disorder. Am J Psychiatry (1989) 0.78
Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy. CNS Drugs (1997) 0.77
An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacology (Berl) (1984) 0.77
Comparative studies on the efficacy of psychotherapy, pharmacotherapy, and their combination in depression: was adequate pharmacotherapy provided? J Clin Psychopharmacol (1989) 0.77
Intracerebroventricular infusion of the CCKB receptor agonist pentagastrin potentiates acoustic startle. Brain Res (1996) 0.77
Effects of PK 8165, a partial benzodiazepine receptor agonist, on cholecystokinin-induced activation of hippocampal pyramidal neurons: a microiontophoretic study in the rat. Eur J Pharmacol (1985) 0.77
Sensitivity to CCK-4 in women with and without premenstrual dysphoric disorder (PMDD) during their follicular and luteal phases. Neuropsychopharmacology (1999) 0.77
Provocative agents in panic disorder. Therapie (1995) 0.77
Role of N-methyl-D-aspartic acid and cholecystokinin receptors in apomorphine-induced aggressive behaviour in rats. Naunyn Schmiedebergs Arch Pharmacol (1995) 0.77
An early Phase II clinical trial with followup of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacol Bull (1985) 0.77
The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers. Biol Psychiatry (1997) 0.77
A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression. J Affect Disord (1994) 0.77
Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze. Neuropharmacology (1994) 0.77
Association study of serotonin-2A receptor gene polymorphism and panic disorder in patients from Canada and Germany. Neurosci Lett (2004) 0.77
Alprazolam 0.125 mg twice a day improves aspects of psychometric performance in healthy volunteers. J Clin Psychopharmacol (1998) 0.76
A schematic representation of the psychopharmacological profile of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry (1996) 0.76
Two faces of cholecystokinin: anxiety and schizophrenia. Fundam Clin Pharmacol (1996) 0.76
Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Am J Psychiatry (1997) 0.76
Behavioral models in mice. Implication of the alpha noradrenergic system. Prog Neuropsychopharmacol Biol Psychiatry (1991) 0.76
Emotional and cognitive factors connected with response to cholecystokinin tetrapeptide in healthy volunteers. Psychiatry Res (1997) 0.76
Efficacy and safety of brofaromine in depression: a Canadian multicenter placebo controlled trial and a review of comparative controlled studies. Clin Neuropharmacol (1992) 0.75
Relationship of panic disorder to posttraumatic stress disorder. Arch Gen Psychiatry (1995) 0.75
Adequacy of pharmacological treatment. Am J Psychiatry (1990) 0.75
Thyroid functioning during treatment for depression. J Psychiatry Neurosci (1993) 0.75
Effect of oral ondansetron on total cholecystokinin plasma levels following CCK-4 panic challenge procedure in healthy men. J Psychiatry Neurosci (1998) 0.75
Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies. Clin Neuropharmacol (1993) 0.75
Using financial incentives to promote shared mental health care. Can J Psychiatry (2002) 0.75
Premenstrual dysphoric disorder and response to cholecystokinin-tetrapeptide. Arch Gen Psychiatry (1995) 0.75
Effects of low doses of lorazepam on psychometric tests in healthy volunteers. Int Clin Psychopharmacol (1994) 0.75
[Clinical and neurobiological aspects of long-term administration of psychotropic drugs]. Can J Psychiatry (1991) 0.75
[Interactions of 5 benzamides with ethanol on various psychopharmacology tests]. Pathol Biol (Paris) (1985) 0.75
[Curarization of the myasthenia patient by atracurium]. Ann Fr Anesth Reanim (1987) 0.75
Vecuronium and atracurium in patients with end-stage renal failure. A comparative study. Br J Anaesth (1987) 0.75
[Mechanism of action of clonidine in the forced-swimming test in mice]. Encephale (1989) 0.75
Lorazepam 0.25 mg twice a day improves aspects of psychometric performance in healthy volunteers. J Psychopharmacol (1995) 0.75
[Gas gangrene of dental origin. Report on four cases (author's transl)]. Rev Stomatol Chir Maxillofac (1981) 0.75
[Total replacement of an arm amputated near the shoulder. Difficulties during anesthesia and ressuscitation (author's transl)]. Anesth Analg (Paris) (1979) 0.75
Influence of alpha stimulants and beta blockers on yohimbine toxicity. Prog Neuropsychopharmacol Biol Psychiatry (1988) 0.75
Relationship between cerebral pharmacokinetics and anxiolytic activity of diazepam and its active metabolites after a single intra-peritoneal administration of diazepam in mice. Hum Psychopharmacol (2002) 0.75
A barbital derivative as an atypical antidepressant drug in mice. Arzneimittelforschung (1987) 0.75